An experimental oral drug for pancreatic cancer has demonstrated improved survival rates in a late-stage clinical trial, offering a rare sign of progress against one of the deadliest forms of the disease. Pancreatic cancer is notoriously difficult to treat, with most patients diagnosed at an advanced stage and few effective therapies available. The trial results raise hopes for a new treatment option in a field that has seen limited breakthroughs in recent decades.